You are here

Roche Pharmaceuticals

Member Since 2018

Daniel O'Day

Chief Executive Officer

Daniel O’Day was appointed CEO Roche Pharmaceuticals in September 2012. Previously, Mr. O’Day was the Chief Operating Officer of the Diagnostics Division starting in January 2010.  

Mr. O’Day acquired extensive commercial experience through diverse roles within Roche worldwide. These began at Roche Pharma in the US where he held various commercial and sales roles between 1987 and 1998. Mr. O’Day then moved to the Roche Pharma headquarters in Switzerland where he held leadership roles in Global Marketing and Lifecycle Management until 2001. Subsequently, he was Head of Corporate Planning at Roche Pharma, in Tokyo, Japan between 2001 and 2003, General Manager at Roche Pharma in Denmark between 2003 and 2006, and President of Roche Molecular Diagnostics in California between 2006 and 2009. 

Mr O’Day obtained a Bachelor of Science in Biology from Georgetown University, Washington, DC, in 1986 and an MBA from Columbia University, New York, NY, in 1997. 

Roche Pharmaceuticals

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: